Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Ndashimye

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Infectious Diseases of Poverty|August 3, 2019
The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030Emmanuel Ndashimye, Eric J Arts
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 16, 2021
Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settingsEmmanuel Ndashimye, Eric J Arts
FEMS Microbiology Reviews|September 21, 2022
New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?Emmanuel Ndashimye, Paul S Reyes, Eric J Arts
Viruses|February 28, 2023
Specialized DNA Structures Act as Genomic Beacons for Integration by Evolutionarily Diverse RetrovirusesHinissan P Kohio, Hannah O Ajoge, Macon D Coleman, et al.
Retrovirology|August 4, 2021
Addressing an HIV cure in LMICSherazaan D Ismail, Joshua Pankrac, Emmanuel Ndashimye, et al.
AIDS Research and Therapy|January 24, 2019
First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in UgandaArt F Y Poon, Emmanuel Ndashimye, Mariano Avino, et al.
AIDS (London, England)|June 4, 2013
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study periodFred Kyeyune, Immaculate Nankya, Samar Metha, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2021
High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutationsEmmanuel Ndashimye, Yue Li, Paul S Reyes, et al.
AIDS Research and Human Retroviruses|January 23, 2018
Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in UgandaEmmanuel Ndashimye, Mariano Avino, Fred Kyeyune, et al.
Nature Communications|January 10, 2023
Antiretroviral APOBEC3 cytidine deaminases alter HIV-1 provirus integration site profilesHannah O Ajoge, Tyler M Renner, Kasandra Bélanger, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Infectious Diseases of Poverty|August 3, 2019
The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030Emmanuel Ndashimye, Eric J Arts
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 16, 2021
Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settingsEmmanuel Ndashimye, Eric J Arts
FEMS Microbiology Reviews|September 21, 2022
New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?Emmanuel Ndashimye, Paul S Reyes, Eric J Arts
Viruses|February 28, 2023
Specialized DNA Structures Act as Genomic Beacons for Integration by Evolutionarily Diverse RetrovirusesHinissan P Kohio, Hannah O Ajoge, Macon D Coleman, et al.
Retrovirology|August 4, 2021
Addressing an HIV cure in LMICSherazaan D Ismail, Joshua Pankrac, Emmanuel Ndashimye, et al.
AIDS Research and Therapy|January 24, 2019
First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in UgandaArt F Y Poon, Emmanuel Ndashimye, Mariano Avino, et al.
AIDS (London, England)|June 4, 2013
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study periodFred Kyeyune, Immaculate Nankya, Samar Metha, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2021
High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutationsEmmanuel Ndashimye, Yue Li, Paul S Reyes, et al.
AIDS Research and Human Retroviruses|January 23, 2018
Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in UgandaEmmanuel Ndashimye, Mariano Avino, Fred Kyeyune, et al.
Nature Communications|January 10, 2023
Antiretroviral APOBEC3 cytidine deaminases alter HIV-1 provirus integration site profilesHannah O Ajoge, Tyler M Renner, Kasandra Bélanger, et al.
Pageof 2